Clik here to view.
Alirocumab is a human monoclonal antibody and a new LDL-cholesterol lowering medication developed by Regeneron Pharmaceuticals and Sanofi . Monoclonal antibodies have the ability to bind to specific targets and unleash a specific action.
These antibodies have been used in so-called immune-therapy and some of the more famous medications already in use are: Humira (Adalimumab which is used in treatment of arthritis, Crohn’s disease and psoriasis), Prolia (Denosumab which is used in treatments of osteoporosis and bone metastasis), Remicade (infliximab used in treatment of rheumatoid arthritis, crohn’s disease, ulcerative colitis and psoriasis).
Are you on any of the medications listed above? Go to my twitter or google plus page and let me know about your experiences using these medications.
Alirocumab is administered by injection under the skin every two weeks. Most of the cholesterol lowering medications are taken orally on a daily basis but alirocumab is different.
I have to mention that there are two other cholesterol lowering medications that have been approved by the Food and Drug Administration (FDA) in 2012 for treatment of familial hypercholesterolemia (high blood cholesterol level) that are administered by injection. These two medications are Juxtapid (lomitapide) and Kynamro (mipomersen).
>>>Next Page (How alirocumab works)
How alirocumab works
Alirocumab: Major side effects
Who should take Alirocumab (Praluent)?
The post Alirocumab: the New Cholesterol Lowering Medication appeared first on TheMedCircle- Dr.Daneschvar.
